99.18 USD
↘ 1.22 (1.22%)AT CLOSE (03:59 PM EDT)
Kodiak Sciences Inc Common Stock
KODNASDAQ • USD
99.75
↗ 0.57 (0.57%)
POST MARKET (AS OF 07:50 PM EDT)
Post Market
AS OF 07:50 PM EDT
99.75
↗ 0.57 (0.57%)
Market: OPEN
Kodiak Sciences Inc Common Stock (KOD) is currently trading at $99.75. The technical outlook is "Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 30, 2026.
Open?$99.41
High?$100.69
Low?$96.58
Prev. Close?$100.40
Volume?568.0K
Avg. Volume?3.0M
VWAP?$98.56
Rel. Volume?0.19x
Bid / Ask
Bid?$83.84 × 100
Ask?$112.59 × 100
Spread?$28.75
Midpoint?$98.22
Valuation & Ratios
Market Cap?6.3B
Shares Out?62.8M
Float?29.6M
Float %?47.1%
P/E Ratio?N/A
P/B Ratio?103.28
EPS?-$3.85
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Employees
124
Market Cap
6.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-04
Address
1250 PAGE MILL RD
PALO ALTO, CA 94304
Phone: 650-281-0850
PALO ALTO, CA 94304
Phone: 650-281-0850
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?48
Piotroski F-Score?0/9Weak
Altman Z-Score?7.37Safe
Confidence?52%Low
Short InterestSqueeze Risk
Short % of Float?28.72%Squeeze Risk
Short Interest?8.5M
Days to Cover?4.2
Free Float29.6M
Avg Daily Volume2.0M
Settlement Date2026-10-15
Financial Health
Current Ratio?2.49Strong
Quick Ratio?2.49Strong
Cash Ratio?2.39Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?103.28HIGH▾
Peers100
S&P3
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-27.0CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-396.1%WEAK▾
S&P3
ROA?-94.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-159902000
Enterprise Value?$6.2B
Fundamentals ratios updated end of day